A multicentre,open-label,prospective,observational study to evaluate effectiveness and safety of repeated intravitreal injections of LucentisÂ® in patients with wet age-related macular degeneration over a 12-month observational period in a real-world setting

Utilizing Ranibizumab intravitreal Injection in a real world setting-A multicentre, open-label, prospective, observational study to evaluate effectiveness and safety of repeated intravitreal injections (IVI) of LucentisÂ® (ranibizumab) in patients with neovascular age-related macular degeneration (AMD) over a 12-month observational period in a real-world setting. - UNVEIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2013/08/003933

Enrollment

3000

Registered

2013-08-29

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients diagnosed with wet Age related Macular Degeneration

Interventions

Intervention1: Intravitreal Ranibizumab: 0.05 ml Intravitreally,once a month for three months and then as when required on PRN basis upto one year

Eligibility

Inclusion criteria

Inclusion criteria: ï¿½ Presence of exudative age-related macular degeneration. ï¿½ Patients for whome a therapy with Lucentisï¿½ is medically indicated. ï¿½ Patients who consent to have their data collected. Patients will not need to consent to taking the drug, as their treatment is decided before entry into the study and is part of their medical care.

Exclusion criteria

Exclusion criteria: Any contra-indication according to local Summary of Product Characteristics or Prescribing Information (SmPC or PI) of Lucentis®.

Design outcomes

Primary

Measure	Time frame
Data of response of Ranibizumab un Indian patients with wet AMDTimepoint: At the end of three months	—

Secondary

Measure	Time frame
Number of injections required for vision stabilityTimepoint: 1 year	—

Countries

India

Contacts

Public ContactDr Ashray Naik

Novartis Healthcare Private Limited

ashray.naik@novartis.com24958579

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026